Ironwood Pharmaceuticals Inc specializes in creating gastrointestinal (GI) treatments, offering relief for conditions like irritable bowel syndrome and chronic constipation through its flagship product, LINZESS. Beyond its core offerings, the company is exploring new therapies for visceral pain and rare diseases, including short bowel syndrome and primary biliary cholangitis. With strategic partnerships enhancing its reach, Ironwood stands out in the healthcare sector for its innovative approach to GI disorders and commitment to improving patient quality of life.
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Tuesday's top analyst upgrades and downgrades included Broadcom, Ciena, Deere, FedEx, IMAX, Ironwood Pharmaceuticals, Lululemon Athletica, LyondellBasell Industries, Nvidia and Starbucks.
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark Therapeutics and Target.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. The firm expects…
Chris Lange After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Lee Jackson The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and Frontier Communications.
Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.
The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel and Valeant Pharmaceuticals.
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at…
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report that the…
